Article

Another success for AADO's conference in NYC

Author(s):

Pamela B. Fritz

Building on its continuing relationship with International Vision Expo, the American Association of Dispensing Ophthalmologists (AADO) has seen consistently increasing attendance at its educational conferences by both ophthalmologists and their practice and optical dispensary management staff.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Floppy iris syndrome risk: Study finds women more susceptible, key drugs identified
March 21st 2025

Floppy iris syndrome risk: Study finds women more susceptible, key drugs identified

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement
March 21st 2025

Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200
March 20th 2025

Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200

Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries
March 20th 2025

Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries

© 2025 MJH Life Sciences

All rights reserved.